(Q47210860)

English

Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report

scientific article published on 15 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

0 references

Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

0 references

1 reference

based on heuristic

inferred from title

author name string

James P Howard

1

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

Alexandra N Nowbar

2

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

Darrel P Francis

3

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

language of work or name

0 references

publication date

15 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

99

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

21

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

1579-1587

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

Variability of office, 24-hour ambulatory, and self-monitored blood pressure measurements

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effect of terminal digit preference on blood pressure measurement and treatment in primary care

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Why are some studies of cardiovascular markers unreliable? The role of measurement variability and what an aspiring clinician scientist can do before it is too late

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

The limit of plausibility for predictors of response: application to biventricular pacing

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Understanding controlled trials. Randomisation methods: concealment

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Emergency department hypertension and regression to the mean

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

How much of the placebo ‘effect’ is really statistical regression?

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Alerting reaction and rise in blood pressure during measurement by physician and nurse.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Twenty-four-hour ambulatory blood pressure measurement in clinical practice and research: a critical review of a technique in need of implementation

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effects of long-acting nifedipine on casual office blood pressure measurements, 24-hour ambulatory blood pressure profiles, exercise parameters and left ventricular mass and function in black patients with mild to moderate systemic hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

The role of spironolactone in the treatment of patients with refractory hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Efficacy of spironolactone therapy in patients with true resistant hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Antihypertensive efficacy of a once a day verapamil SR/trandolapril combination.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Amlodipine 2.5 mg once daily in older hypertensives: a Brazilian multi-centre study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Combination treatment in hypertension: the VeraTran Study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effects of Renal Sympathetic Denervation on 24-hour Blood Pressure Variability

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Renal denervation in moderate to severe CKD.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the ‘white-coat’ effect

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

A Smooth Blood Pressure Control is obtained over 24 h by Delapril in Mild to Moderate Essential Hypertensives

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Clinical trials with ambulatory blood pressure monitoring: fewer patients needed?

1 reference

https://api.crossref.org/works/10.1136%2FHEARTJNL-2013-304238

21 January 2018

Identifiers

10.1136/HEARTJNL-2013-304238

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/24038167

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47210860&oldid=2146415730"